A Randomized, Controlled Trial to Evaluate the Efficacy of Substituting Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors in Individuals With Virologic Suppression for at Least 12 Weeks.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Darunavir; HIV protease inhibitors; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- 21 Jul 2017 Biomarkers information updated
- 09 Feb 2012 Actual end date changed from Jan 2009 to Feb 2010 as reported by ClinicalTrials.gov.
- 26 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.